Helix BioPharma Corp Initiates Enrollment In The Second Dosing Cohort Of U.S. Combination Treatment Study Of Its Lung Cancer Drug Candidate L-DOS47

Helix BioPharma Corp Initiates Enrollment In The Second Dosing Cohort Of U.S. Combination Treatment Study Of Its Lung Cancer Drug Candidate L-DOS47 (Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening in the second dosing cohort of its ongoing U.S. study of L-DOS47 in combination treatment with pemetrexed/carboplatin (“LDOS001”). Helix-PR-01212016.pdf Helix-PR-01212016-1.pdf

The release as fetched from its publisher. helixbiopharma.com ↗